A Phase 2 interventional study of Cetuximab in Advanced Cancer, sponsored by Eli Lilly and Company. Completed at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-24.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine whether corrected QT (QTc) interval changes occur on an electrocardiogram (ECG) when cetuximab is administered to the study population.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Cetuximab
Cetuximab administered by intravenous (IV) infusion at an initial dose of 400 mg/m\^2 over 120 minutes on Day 1 followed by a weekly maintenance IV dose of 250 mg/m\^2 over 60 minutes.
Also known as: Erbitux
Number of Participants With Clinically Meaningful Prolongation of the QT Interval Corrected for Heart Rate (QTc) From Time-matched Baseline
12-Lead continuous digital electrocardiogram (ECG) data were collected at preselected time points at baseline visit and on Days 1, 8, 15, 22, and 29. The QT interval is the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. The corrected QTc is the QT interval corrected for heart rate. Prolongation of the QTc was identified as clinically meaningful at the investigator's discretion.
Time frame: Baseline, Day 1, and then weekly to end of Cycle 1 (28 days)
Mean Change in QTc From Time-matched Baseline Assessed Using Fridericia's Correction Formula (QTcF) by Study Day and Time Point
The QT interval is the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. The QTc is the QT interval corrected for heart rate. The QTcF=QT/RR\^1/3, where RR=RR interval in seconds. Baseline=predose. Mean change in QTc interval from baseline to time t=QTc interval at time t minus QTc interval at baseline.
Time frame: Predose Day 1 (Baseline) to end of Cycle 1 (28 days)
Number of Participants With Clinically Significant Changes in PR Interval, QRS Interval, and Heart Rate
12-Lead continuous digital ECG data were collected at preselected time points at baseline visit and on Days 1, 8, 15, 22, and 29. The PR interval is the time from the onset of the P wave to the beginning of the QRS complex. The QRS interval=deflections in the ECG, comprising Q, R, and S waves, that represent depolarization of the ventricles. Clinically significant was determined at the investigator's discretion.
Time frame: Baseline, Day 1, and then weekly to end of Cycle 1 (28 days)
Number of Participants With Death, Treatment-related Death, Serious Adverse Events (SAEs), Treatment-related SAEs, Adverse Events (AEs) Leading to Discontinuation, and Treatment-related AEs Leading to Discontinuation
AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with treatment. SAE=any untoward medical occurrence that at any dose results in death, is life-threatening, requires or prolongs inpatient hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, or is an important medical event. Treatment related=possibly, probably, or certainly related to or of unknown relationship to study treatment.
Time frame: Baseline through Cycle 1 (28 days), continuously
Number of Participants With AEs of Special Interest by Worst Common Terminology Criteria (CTC) Grade
AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with treatment. AEs of special interest have been sponsor-selected based on the known clinical effects of cetuximab. Treatment related=possibly, probably, or certainly related to or of unknown relationship to study treatment. CTC Grade 1: Mild. Grade 2: Moderate. Grade 3: Severe or medically significant but not immediately life-threatening. Grade 4: Life-threatening.
Time frame: Baseline through Cycle 1 (28 days), continuously
Number of Participants With Serum Chemistry Abnormalities by Worst CTC Grade at Baseline and On-study
BL=baseline; OS=on-study; ULN=upper level of normal. Albumin,low (g/dL) Grade 1:\<LLN-30, Grade 2:\<30-20, Grades 3\&4:\<20. Aspartate aminotransferase (AST)(U/L) Grade 1:\>ULN-2.5\*ULN, Grade 2:\>2.5-5.0\*ULN, Grade 3:\>5.0-20.0\*ULN, Grade 4:\>20.0\*ULN. Total bilirubin, high Grade 1:ULN-1.5\*ULN, Grade 2:\>1.5-3.0\*ULN, Grade 3:\>3.0-10.0\*ULN, Grade 4:\>10.0\*ULN. Alkaline phosphatase (ALP) (U/L) Grade 1:\>ULN-2.5\*ULN, Grade 2:\>2.5-5.0\*ULN, Grade 3:\>5.0-20.0\*ULN, Grade 4:\>20.0\*ULN. Creatinine (mg/dL) Grade 1:\>ULN-1.5\*ULN, Grade 2:\>1.5-3.0\*ULN, Grade 3:\>3.0-6.0\*ULN, Grade 4:\>6.0\*ULN.
Time frame: At screening, at the end of Cycle 1 (28 days)
Number of Participants With Serum Chemistry Abnormalities by Worst CTC Grade at Baseline and On-study (Continued)
BL=baseline; OS=on-study; LLN=lower level of normal; ULN=upper level of normal. Sodium, low(mmol/L) Grades 1\&2:\<LLN-130, Grade 3:\<130-120, Grade 4:\<120. Sodium, high (mmol/L) Grade 1:\>ULN-150, Grade 2:\>150-155, Grade 3:\>155-160, Grade 4:\>160. Potassium, high (mmol/L) Grade 1:\>ULN-5.5, Grade 2:\>5.5-6.0, Grade 3:\>6.0-7.0, Grade 4:\>7.0. Glucose, low(mg/dL) Grade 1:\<LLN-55, Grade 2:\<55-40, Grade 3:\<40-30, Grade 4:\<30. Glucose, high (mg/dL) Grade 1:\>ULN-160, Grade 2:\>160-250, Grade 3:\>250-500, Grade 4:\>500. Calcium, high(mg/dL) Grade 1:\>ULN-11.5, Grade 2:\>11.5-12.5, Grade 3:\>12.5-13.5, Grade 4:\>13.
Time frame: At screening, at the end of Cycle 1 (28 days)
Number of Participants With Hematology Abnormalities by Worst CTC Grade at Baseline and On-study
BL=baseline; OS=on-study; LLN=lower level of normal. Laboratory values assessed using CTC for AEs, Version 3.0. Hemoglobin (g/dL) Grade 1:\<LLN to 10.0, Grade 2:\<10.0 to 8.0, Grade 3:\<8.0 to 6.5, Grade 4:\<6.5. Platelets Grade 1:LLN to 75.0\*10\^9/L, Grade 2:\<75.0 to 50.0\*10\^9/L, Grade 3:\<50.0 to 25.0\*10\^9/L, Grade 4:\<25.0 to 10\^9/L. White blood cells Grade 1:\<LLN to 3.0\*10\^9/L, Grade 2:\<3.0 to 2.0\*10\^9/L, Grade 3:\<2.0 to 1.0\*10\^9/L, Grade 4:\<1.0\*10\^9/L. Neutrophils Grade 1:\<LLN to 1.5\*10\^9/L, Grade 2:\<1.5 to 1.0\*10\^9/L, Grade 3:\<1.0 to 0.5\*10\^9/L, Grade 4:\<0.5\*10\^9/L.
Time frame: At screening, weekly prior to start of cetuximab infusion, at end of Cycle 1 (28 days), and at 30-day follow-up
| Milestone | Cetuximab |
|---|---|
| Started | 51 |
| Completed | 33 |
| Not completed | 18 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Adverse event | 3 |
| Withdrew: Disease progression | 7 |
| Withdrew: Failure to meet eligibility criteria | 2 |
| Withdrew: Study drug toxicity | 2 |
| Withdrew: Other | 2 |
12-Lead continuous digital electrocardiogram (ECG) data were collected at preselected time points at baseline visit and on Days 1, 8, 15, 22, and 29. The QT interval is the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. The corrected QTc is the QT interval corrected for heart rate. Prolongation of the QTc was identified as clinically meaningful at the investigator's discretion.
| Participants | Cetuximab |
|---|---|
| Number of Participants With Clinically Meaningful Prolongation of the QT Interval Corrected for Heart Rate (QTc) From Time-matched Baseline | 0 |
12-Lead continuous digital ECG data were collected at preselected time points at baseline visit and on Days 1, 8, 15, 22, and 29. The PR interval is the time from the onset of the P wave to the beginning of the QRS complex. The QRS interval=deflections in the ECG, comprising Q, R, and S waves, that represent depolarization of the ventricles. Clinically significant was determined at the investigator's discretion.
| Participants | Cetuximab |
|---|---|
| Changes in PR interval | 0 |
| Changes in QRS interval | 0 |
| Changes in heart rate | 0 |
AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with treatment. SAE=any untoward medical occurrence that at any dose results in death, is life-threatening, requires or prolongs inpatient hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, or is an important medical event. Treatment related=possibly, probably, or certainly related to or of unknown relationship to study treatment.
| Participants | Cetuximab |
|---|---|
| Deaths | 6 |
| Treatment-related deaths | 0 |
| SAEs | 16 |
| Treatment-related SAEs | 2 |
| AEs leading to discontinuation | 10 |
| Treatment-related AEs leading to discontinuation | 3 |
AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with treatment. AEs of special interest have been sponsor-selected based on the known clinical effects of cetuximab. Treatment related=possibly, probably, or certainly related to or of unknown relationship to study treatment. CTC Grade 1: Mild. Grade 2: Moderate. Grade 3: Severe or medically significant but not immediately life-threatening. Grade 4: Life-threatening.
| Participants | Cetuximab |
|---|---|
| Infusion reaction (Any grade) | 6 |
| Infusion reaction (Grade 3) | 2 |
| Infusion reaction (Grade 4 or 5) | 0 |
| Acneform rash (Any grade) | 32 |
| Acneform rash (Grade 3) | 1 |
| Acneform rash (Grade 4 or 5) | 0 |
| Cardiac event (Any grade) | 2 |
| Cardiac event (Grade 3) | 1 |
| Cardiac event (Grade 4 or 5) | 0 |
| Treatment-related infusion reaction (Any grade) | 6 |
| Treatment-related infusion reaction (Grade 3) | 2 |
| Treatment-related infusion reaction (Grade 4 or 5) | 0 |
| Treatment-related acneform rash (Any grade) | 31 |
| Treatment-related acneform rash (Grade 3) | 1 |
| Treatment-related acneform rash (Grade 4 or 5) | 0 |
| Treatment-related cardiac event (Any grade) | 0 |
| Treatment-related cardiac event (Grade 3) | 0 |
| Treatment-related cardiac event (Grade 4 or 5) | 0 |
BL=baseline; OS=on-study; ULN=upper level of normal. Albumin,low (g/dL) Grade 1:\<LLN-30, Grade 2:\<30-20, Grades 3\&4:\<20. Aspartate aminotransferase (AST)(U/L) Grade 1:\>ULN-2.5\*ULN, Grade 2:\>2.5-5.0\*ULN, Grade 3:\>5.0-20.0\*ULN, Grade 4:\>20.0\*ULN. Total bilirubin, high Grade 1:ULN-1.5\*ULN, Grade 2:\>1.5-3.0\*ULN, Grade 3:\>3.0-10.0\*ULN, Grade 4:\>10.0\*ULN. Alkaline phosphatase (ALP) (U/L) Grade 1:\>ULN-2.5\*ULN, Grade 2:\>2.5-5.0\*ULN, Grade 3:\>5.0-20.0\*ULN, Grade 4:\>20.0\*ULN. Creatinine (mg/dL) Grade 1:\>ULN-1.5\*ULN, Grade 2:\>1.5-3.0\*ULN, Grade 3:\>3.0-6.0\*ULN, Grade 4:\>6.0\*ULN.
| Participants | Cetuximab |
|---|---|
| Albumin, low (BL, Grades 1-4) ( N=48) | 18 |
| Albumin, low (OS, Grade 1-4) ( N=45) | 27 |
| Albumin, low (BL, Grades 3 or 4) ( N=48) | 0 |
| Albumin, low (OS, Grades 3 or 4) ( N=45) | 0 |
| Albumin, low (BL, Grade 4) (N=48) | 0 |
| Albumin, low (OS, Grade 4) (N=45) | 0 |
| AST, high (BL, Grades 1-4) ( N=48) | 9 |
| AST, high (OS, Grades 1- 4) ( N=45) | 19 |
| AST, high (BL, Grades 3 or 4) ( N=48) | 1 |
| AST, high (OS, Grades 3 or 4) ( N=45) | 2 |
| AST, high (BL, Grade 4) ( N=48) | 0 |
| AST, high (OS, Grade 4) ( N=45) | 0 |
| Total bilirubin, high (BL, Grades 1-4) ( N=48) | 2 |
| Total bilirubin, high (OS, Grades 1-4) ( N=45) | 4 |
| Total bilirubin, high (BL, Grades 3 or 4) ( N=48) | 0 |
| Total bilirubin, high (OS, Grades 3 or 4) (N=45) | 1 |
| Total bilirubin, high (BL, Grade 4) ( N=48) | 0 |
| Total bilirubin, high (OS, Grade 4) ( N=45) | 0 |
| ALP, high (BL, Grade 1-4) ( N=48) | 18 |
| ALP, high (OS, Grade 1-4) ( N=45) | 25 |
| ALP, high (BL, Grade 3 or 4) ( N=48) | 1 |
| ALP, high (OS, Grade 3 or 4) ( N=45) | 2 |
| ALP, high (BL, Grade 4) ( N=48) | 0 |
| ALP, high (OS, Grade 4) ( N=45) | 0 |
| Creatinine, high (BL, Grades 1-4) ( N=48) | 1 |
| Creatinine, high (OS, Grade 1-4) ( N=45) | 2 |
| Creatinine, high (BL, Grades 3 or 4) ( N=48) | 0 |
| Creatinine, high (OS, Grades 3 or 4) ( N=45) | 0 |
| Creatinine, high (BL, Grade 4) ( N=48) | 0 |
| Creatinine, high (OS, Grade 4) ( N=45) | 0 |
BL=baseline; OS=on-study; LLN=lower level of normal; ULN=upper level of normal. Sodium, low(mmol/L) Grades 1\&2:\<LLN-130, Grade 3:\<130-120, Grade 4:\<120. Sodium, high (mmol/L) Grade 1:\>ULN-150, Grade 2:\>150-155, Grade 3:\>155-160, Grade 4:\>160. Potassium, high (mmol/L) Grade 1:\>ULN-5.5, Grade 2:\>5.5-6.0, Grade 3:\>6.0-7.0, Grade 4:\>7.0. Glucose, low(mg/dL) Grade 1:\<LLN-55, Grade 2:\<55-40, Grade 3:\<40-30, Grade 4:\<30. Glucose, high (mg/dL) Grade 1:\>ULN-160, Grade 2:\>160-250, Grade 3:\>250-500, Grade 4:\>500. Calcium, high(mg/dL) Grade 1:\>ULN-11.5, Grade 2:\>11.5-12.5, Grade 3:\>12.5-13.5, Grade 4:\>13.
| Participants | Cetuximab |
|---|---|
| Sodium, low (BL, Grades 1-4) ( N=48) | 0 |
| Sodium, low (OS, Grades 1- 4) ( N=45) | 7 |
| Sodium, low (BL, Grades 3 or 4) ( N=48) | 15 |
| Sodium, low (OS, Grades 3 or 4) ( N=45) | 2 |
| Sodium, low (BL, Grade 4) ( N=48) | 0 |
| Sodium, low (OS, Grade 4) ( N=45) | 0 |
| Sodium, high (BL, Grade 1-4) ( N=48) | 1 |
| Sodium, high (OS, Grades 1-4) ( N=45) | 5 |
| Sodium, high (BL, Grades 3 or 4) ( N=48) | 0 |
| Sodium, high (OS, Grades 3 or 4) ( N=45) | 0 |
| Sodium, high (BL, Grade 4) ( N=48) | 0 |
| Sodium, high (OS, Grade 4) ( N=45) | 0 |
| Potassium, high (BL, Grades 1-4) ( N=48) | 2 |
| Potassium, high (OS, Grades 1-4) ( N=45) | 3 |
| Potassium, high (BL, Grade 3 or 4) ( N=48) | 0 |
| Potassium, high (OS, Grade 3 or 4) ( N=45) | 1 |
| Potassium, high (BL, Grade 4) ( N=48) | 0 |
| Potassium, high (OS, Grade 4) ( N=45) | 0 |
| Glucose, low (BL, Grades 1- 4) ( N=48) | 0 |
| Glucose, low (OS, Grades 1-4) ( N=45) | 2 |
| Glucose, low (BL, Grades 3 or 4) ( N=48) | 0 |
| Glucose, low (OS, Grades 3 or 4) ( N=45) | 0 |
| Glucose, low (BL, Grade 4) ( N=48) | 0 |
| Glucose, low (OS, Grade 4) ( N=45) | 0 |
| Glucose, high (BL, Grades 1- 4) ( N=48) | 29 |
| Glucose, high (OS, Grades 1- 4) ( N=45) | 37 |
| Glucose, high (BL, Grades 3 or 4) (N=48) | 2 |
| Glucose, high (OS, Grades 3 or 4) (N=45) | 4 |
| Glucose, high (BL, Grade 4) (N=48) | 0 |
| Glucose, high (OS, Grade 4) (N=45) | 0 |
| Calcium, low (BL, Grade 1-4) (N=48) | 4 |
| Calcium, low (OS, Grade 1-4) (N=45) | 14 |
| Calcium, low (BL, Grade 3 or 4) (N=48) | 0 |
| Calcium, low (OS, Grades 3 or 4) (N=45) | 0 |
| Calcium, low (BL, Grade 4) (N=48) | 0 |
| Calcium, low (OS, Grade 4) (N=45) | 0 |
| Calcium, high (BL, Grades 1-4) (N=48) | 2 |
| Calcium, high (OS, Grades 1-4) (N=45) | 2 |
| Calcium, high (BL, Grades 3 or 4) (N=48) | 0 |
| Calcium, high (OS, Grades 3 or 4) (N=45) | 0 |
| Calcium, high (BL, Grade 4) (N=48) | 0 |
| Calcium, high (OS, Grade 4) (N=45) | 0 |
| Magnesium, low (BL, Grades 1-4) (N=41) | 3 |
| Magnesium, low (OS, Grades 1-4) (N=38) | 11 |
| Magnesium, low (BL, Grades 3 or 4) (N=41) | 0 |
| Magnesium, low (OS, Grades 3 or 4) (N=38) | 1 |
| Magnesium, low (BL, Grade 4) (N=41) | 0 |
| Magnesium, low (OS, Grade 4) (N=38) | 1 |
The QT interval is the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. The QTc is the QT interval corrected for heart rate. The QTcF=QT/RR\^1/3, where RR=RR interval in seconds. Baseline=predose. Mean change in QTc interval from baseline to time t=QTc interval at time t minus QTc interval at baseline.
| msec | Cetuximab |
|---|---|
| Day 1 (N=36) Predose | 3.8 ± 2.5 |
| Day 1 (N=37) 1 hour | 1.8 ± 1.9 |
| Day 1 (N=37) 2 hour | 0.7 ± 2.1 |
| Day 1 (N=36) 3 hour | 1.2 ± 1.6 |
| Day 1 (N=37) 6 hour | -2.4 ± 1.8 |
| Day 8 (N=37) Predose | 1.3 ± 2.2 |
| Day 8 (N=37) 1 hour | 1.9 ± 2.5 |
| Day 8 (N=37) 2 hour | 4.5 ± 2.7 |
| Day 8 (N=36) 3 hour | 0.8 ± 2.5 |
| Day 15 (N=37) Predose | 3.2 ± 2.7 |
| Day 15 (N=37) 1 hour | 2.6 ± 3.1 |
| Day 15 (N=37) 2 hour | 1.2 ± 3.2 |
| Day 15 (N=36) 3 hour | -0.7 ± 3.6 |
| Day 22 (N=37) Predose | 2.3 ± 3.3 |
| Day 22 (N=37) 1 hour | 3.4 ± 2.9 |
| Day 22 (N=37) 2 hour | 4.1 ± 3.2 |
| Day 22 (N=36) 3 hour | 2.2 ± 2.8 |
| Day 22 (N=37) 6 hour | 2.6 ± 2.4 |
| Day 29 (N=30) Predose | 0.0 ± 3.4 |
| Day 29 (N=30) 1 hour | 3.5 ± 2.9 |
| Day 29 (N=30) 2 hour | 3.5 ± 2.7 |
| Day 29 (N=29) 3 hour | 4.0 ± 3.0 |
BL=baseline; OS=on-study; LLN=lower level of normal. Laboratory values assessed using CTC for AEs, Version 3.0. Hemoglobin (g/dL) Grade 1:\<LLN to 10.0, Grade 2:\<10.0 to 8.0, Grade 3:\<8.0 to 6.5, Grade 4:\<6.5. Platelets Grade 1:LLN to 75.0\*10\^9/L, Grade 2:\<75.0 to 50.0\*10\^9/L, Grade 3:\<50.0 to 25.0\*10\^9/L, Grade 4:\<25.0 to 10\^9/L. White blood cells Grade 1:\<LLN to 3.0\*10\^9/L, Grade 2:\<3.0 to 2.0\*10\^9/L, Grade 3:\<2.0 to 1.0\*10\^9/L, Grade 4:\<1.0\*10\^9/L. Neutrophils Grade 1:\<LLN to 1.5\*10\^9/L, Grade 2:\<1.5 to 1.0\*10\^9/L, Grade 3:\<1.0 to 0.5\*10\^9/L, Grade 4:\<0.5\*10\^9/L.
| Participants | Cetuximab |
|---|---|
| Hemoglobin, low (BL, Grades 1-4) (N=51) | 35 |
| Hemoglobin, low (OS, Grades 1-4) (N=45) | 34 |
| Hemoglobin, low (BL, Grades 3 or 4) (N=51) | 1 |
| Hemoglobin, low (OS, Grades 3 or 4) (N=45) | 2 |
| Hemoglobin, low (BL, Grade 4) (N=51) | 0 |
| Hemoglobin, low (OS, Grade 4) (N=45) | 0 |
| Platelets, low (BL, Grades 1-4) (N=51) | 8 |
| Platelets, low (OS, Grades 1-4) (N=45) | 9 |
| Platelets, low (BL, Grades 3 or 4) (N=51) | 0 |
| Platelets, low (OS, Grades 3 or 4) (N=45) | 0 |
| Platelets, low (BL, Grade 4) (N=51) | 0 |
| Platelets, low (OS, Grade 4) (N=45) | 0 |
| White blood cells, low (BL, Grades 1-4) (N=51) | 4 |
| White blood cells, low (OS, Grades 1-4) (N=45) | 13 |
| White blood cells, low (BL, Grades 3 or 4) (N=51) | 0 |
| White blood cells, low (OS, Grades 3 or 4) (N=45) | 0 |
| White blood cells, low (BL, Grade 4) (N=51) | 0 |
| White blood cells, low (OS, Grade 4) (N=45) | 0 |
| Neutrophils, low (BL, Grades 1-4) (N=47) | 0 |
| Neutrophils, low (OS, Grades 1-4) (N=44) | 5 |
| Neutrophils, low (BL, Grade 3 or 4) (N=47) | 0 |
| Neutrophils, low (OS, Grade 3 or 4) (N=44) | 1 |
| Neutrophils, low (BL, Grade 4) (N=47) | 0 |
| Neutrophils, low (OS, Grade 4) (N=44) | 0 |
Collected over Baseline through Cycle 1 (28 days) and up to 30 following last dose of study medication (totaling up to 58 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cetuximab | — | 16/51 (31.4%) | 43/51 (84.3%) |
| Event | Cetuximab |
|---|---|
| DISEASE PROGRESSIONGeneral disorders | 4/51 |
| ACUTE CORONARY SYNDROMECardiac disorders | 1/51 |
| HEADACHENervous system disorders | 1/51 |
| ASCITESGastrointestinal disorders | 1/51 |
| DISTAL INTESTINAL OBSTRUCTION SYNDROMEGastrointestinal disorders | 1/51 |
| SEPSISInfections and infestations | 1/51 |
| HYDRONEPHROSISRenal and urinary disorders | 1/51 |
| INCISIONAL HERNIAInjury, poisoning and procedural complications | 1/51 |
| JOINT DISLOCATIONInjury, poisoning and procedural complications | 1/51 |
| NECK PAINMusculoskeletal and connective tissue disorders | 1/51 |
| Event | Cetuximab |
|---|---|
| RASHSkin and subcutaneous tissue disorders | 22/51 |
| HEADACHENervous system disorders | 11/51 |
| DERMATITIS ACNEIFORMSkin and subcutaneous tissue disorders | 9/51 |
| NAUSEAGastrointestinal disorders | 6/51 |
| FATIGUEGeneral disorders | 5/51 |
| VOMITINGGastrointestinal disorders | 4/51 |
| DIARRHOEAGastrointestinal disorders | 4/51 |
| ABDOMINAL PAINGastrointestinal disorders | 4/51 |
| URINARY TRACT INFECTIONInfections and infestations | 4/51 |
| PYREXIAGeneral disorders | 4/51 |
| Age, Continuous(years) | Cetuximab |
|---|---|
| Mean | 61 ± 12 |
| Sex: Female, Male(Participants) | Cetuximab |
|---|---|
| Female | 21 |
| Male | 30 |
| Race (NIH/OMB)(Participants) | Cetuximab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 4 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 45 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
The record gives a start of Feb 2009, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cetuximab